Verici Dx — LSE:VRCI — is in focus after the latest corporate development: Fundraising announcement puts diagnostic development funding in focus. The company is traded on the London Stock Exchange’s AIM market, rather than being a constituent of the FTSE 100 or FTSE 250. …
ECO Animal Health Group — LSE:EAH — is in focus after the latest corporate development: Shareholding notification updates the ownership picture. The company is traded on the London Stock Exchange’s AIM market, rather than being a constituent of the FTSE 100 or FTSE 250. …
Advanced Medical Solutions Group is in focus following investor disclosure and corporate updates. The announcement matters because it may influenceShareholderexpectations,Capitalallocation, governance or the company’s strategic direction. Investors should separate the confirmed transaction or disclosure from assumptions about future performance.
Tristel develops and manufactures infection prevention products based on its proprietary chlorine dioxide chemistry. Its main market is the decontamination of reusable medical devices that cannot be sterilised by heat, such as ultrasound probes and endoscopes, which are used in hospitals and clinics. The …
ValiRx describes itself as focused on early-stage cancer therapeutics and women's health. Its model is to select and develop drug candidates and then partner or out-license them, often through dedicated subsidiaries. Its research arm, Inaphaea BioLabs, holds a biobank of patient-derived cell models and …
Taken together, the announcements mark a period of transition for the group, withLeadershipchange coinciding with an activeCapitalreturn programme.
Verici Dx develops and sells RNA-based tests designed to help clinicians manage kidney transplant patients. Its lead commercial product, Tutivia, is a blood test for acute rejection after a kidney transplant in the United States, and it runs tests through its own CLIA-certified, CAP-accredited …
Thalia is a biotechnology company focused on RNA-based therapies. Before its rebrand, theBusinessoperated as N4 Pharma, which had been developing Nuvec, a delivery technology for nucleic acid medicines. The company announced the appointment of a new chief executive alongside a proposed name change, a …
TheraCryf is a biotechnology company based at Alderley Park in Cheshire. It develops medicines for addiction and other neuropsychiatric disorders using a capital-light, virtual model, aiming to advance programmes to early clinical or proof-of-concept stage before partnering them with larger pharmaceutical or biotech groups.
The company's recent reporting showed that Shield had reachedCash Flowpositivity asRevenuegrew, and that its loss had shrunk as milestone andRoyaltyreceipts increased. The shares jumped 11 per cent on one occasion as losses narrowed and the company held its profitability target.